| 000 | 01123 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517042904.0 | ||
| 264 | 0 | _c20160610 | |
| 008 | 201606s 0 0 eng d | ||
| 022 | _a1744-7682 | ||
| 024 | 7 |
_a10.1517/14712598.2015.1069273 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFlamant, Mathurin | |
| 245 | 0 | 0 |
_aCould therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment? _h[electronic resource] |
| 260 |
_bExpert opinion on biological therapy _c2015 |
||
| 300 |
_a1657-60 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAzathioprine _xmetabolism |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xmetabolism |
| 650 | 0 | 4 |
_aInflammatory Bowel Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aInfliximab _xmetabolism |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _ximmunology |
| 700 | 1 | _aRoblin, Xavier | |
| 773 | 0 |
_tExpert opinion on biological therapy _gvol. 15 _gno. 11 _gp. 1657-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14712598.2015.1069273 _zAvailable from publisher's website |
| 999 |
_c25089402 _d25089402 |
||